Skip to search formSkip to main contentSkip to account menu

SNS 314

Known as: Aurora Kinase Inhibitor SNS-314, SNS-314, SNS314 
A synthetic small molecule Aurora kinase (AK) inhibitor with potential antineoplastic activity. Aurora kinase inhibitor SNS-314 selectively binds to… 
National Institutes of Health

Related topics

Related topics

6 relations
Aurora Kinase AInhibition of Cell ProliferationNCIt Antineoplastic Agent TerminologySignal Transduction Inhibition

Broader (2)

Phenylurea CompoundsThiazoles

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
The aurora kinase inhibitor VX-680 shows anti-cancer effects in primary metastatic cells and the SW13 cell line
New therapeutic targets are needed to fight cancer. Aurora kinases (AK) were recently identified as vital key regulators of cell… 
2012
2012
Effects of the Aurora kinases pan-inhibitor SNS-314 mesylate on anaplastic thyroid cancer derived cell lines.
OBJECTIVES Anaplastic thyroid carcinomas (ATC) are highly aggressive tumours unresponsive to any available radio- or… 
2010
2010
3D-QSAR and Molecular Docking Studies on Derivatives of MK-0457, GSK1070916 and SNS-314 as Inhibitors against
Abstract: Development of anticancer drugs targeting Aurora B, an important member of the serine/threonine kinases family, has… 
2009
2009
Gateways to clinical trials.
(-)-Gossypol; Alemtuzumab, Amlodipine, Anakinra, Azacitidine; Bazedoxifene acetate, Belinostat, Bevacizumab, BI-201335, BI-2536… 
2008
2008
Phase 1 trial of SNS-314, a novel selective inhibitor of aurora kinases A, B, and C, in advanced solid tumor patients
2008
2008
283 POSTER Phase 1 trial of SNS-314, a novel selective inhibitor of Aurora kinases A, B, and C, in advanced solid tumor patients
2007
2007
502 POSTER SNS-314, a selective Aurora kinase inhibitor with potent, pre-clinical antitumour activity, shows broad therapeutic potential in combination with standard chemotherapeutics and synergy…
2007
2007
378 POSTER Non-clinical pharmacokinetics, distribution and excretion of SNS-314, a novel, selective aurora kinase inhibitor
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)